Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Endometriosis testing is escaping the surgery-first era. Saliva, blood and imaging tools now face the harder test: clinical utility.
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
BrioHealth Solutions has received United States Food and Drug Administration conditional approval to initiate the Brio4Kids Trial, a pediatric clinical evaluation of the BrioVAD System in children with advanced heart failure. The trial will proceed under the existing Investigational Device Exemption for the INNOVATE Trial, giving the medical device developer a defined pathway to test […]
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a […]
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.
Propanc Biopharma expands Spanish research alliances ahead of first human oncology trials. Discover what this means for PRP development and strategy.